Published in Southeast Asian J Trop Med Public Health on September 01, 2004
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J (2011) 1.56
Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob Agents Chemother (2009) 1.12
Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother (2014) 1.07
First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother (2008) 1.07
Pharmacokinetics and bioequivalence evaluation of two fixed-dose tablet formulations of dihydroartemisinin and piperaquine in Vietnamese subjects. Antimicrob Agents Chemother (2008) 1.02
Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur J Clin Pharmacol (2006) 1.01
Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration. Eur J Clin Pharmacol (2008) 0.93
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol (2014) 0.92
Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J (2009) 0.83
Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults. Malar J (2015) 0.81
Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis. Oncotarget (2016) 0.77
Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria. Am J Trop Med Hyg (2014) 0.76
Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer. J Exp Clin Cancer Res (2017) 0.75
Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Br J Clin Pharmacol (2017) 0.75
Averting a malaria disaster. Lancet (1999) 9.40
Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis (1989) 8.24
Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol (1985) 7.14
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N Engl J Med (1982) 6.73
An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol (1994) 5.34
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg (1999) 4.60
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health (2004) 4.35
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Effects of Plasmodium vivax malaria in pregnancy. Lancet (1999) 3.62
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg (2001) 3.32
Classification criteria for polymyositis and dermatomyositis. J Rheumatol (1995) 3.08
Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med (1983) 3.07
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg (2001) 3.03
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (1999) 2.98
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med (1982) 2.71
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (1998) 2.61
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother (2001) 2.40
Bacteriological studies of the venom and mouth cavities of wild Malayan pit vipers (Calloselasma rhodostoma) in southern Thailand. Trans R Soc Trop Med Hyg (1991) 2.38
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis (2000) 2.35
Antigen-specific immunosuppression in human malaria due to Plasmodium falciparum. J Infect Dis (1986) 2.18
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmacol Ther (1999) 2.16
Severe neurotoxic envenoming by the Malayan krait Bungarus candidus (Linnaeus): response to antivenom and anticholinesterase. Br Med J (Clin Res Ed) (1983) 2.15
ParaSight-F test for the detection of treatment failure in multidrug resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg (1996) 2.13
Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. N Engl J Med (1985) 2.12
Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg (2000) 2.10
Intestinal helminth infections are associated with increased incidence of Plasmodium falciparum malaria in Thailand. J Parasitol (2002) 2.07
Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report. Southeast Asian J Trop Med Public Health (1991) 2.06
Correlation of serum IgG antibodies to recombinant P0 fusion protein with IgG antibodies to carboxyl-terminal 22 synthetic peptides and carboxyl-terminal 22 amino acid-deleted recombinant P0 fusion protein in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.06
Parasite multiplication potential and the severity of Falciparum malaria. J Infect Dis (2000) 2.00
Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg (1994) 1.93
The importance of anaemia in cerebral and uncomplicated falciparum malaria: role of complications, dyserythropoiesis and iron sequestration. Q J Med (1986) 1.90
Retinal hemorrhage, a common sign of prognostic significance in cerebral malaria. Am J Trop Med Hyg (1983) 1.74
Binding of quinine to plasma proteins in falciparum malaria. Am J Trop Med Hyg (1985) 1.73
Enumeration of activated thymus-derived lymphocytes by the virus plaque assay. Proc Natl Acad Sci U S A (1973) 1.67
Ascaris lumbricoides infection is associated with protection from cerebral malaria. Parasite Immunol (2000) 1.65
Quinidine in falciparum malaria. Lancet (1981) 1.65
Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol (2006) 1.64
Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J Infect Dis (1989) 1.64
Evaluation of a new Plasmodium lactate dehydrogenase assay (OptiMAL-IT) for the detection of malaria. Trans R Soc Trop Med Hyg (2005) 1.62
Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis (2001) 1.62
Pathophysiological and prognostic significance of cerebrospinal-fluid lactate in cerebral malaria. Lancet (1985) 1.61
Qualitative and semiquantitative polymerase chain reaction to predict Plasmodium falciparum treatment failure. J Infect Dis (1994) 1.61
Mechanisms of lymphocyte adhesion to human vascular endothelial cells in culture. T lymphocyte adhesion to endothelial cells through endothelial HLA-DR antigens induced by gamma interferon. J Clin Invest (1986) 1.60
Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother (2008) 1.55
Cerebral anaerobic glycolysis and reduced cerebral oxygen transport in human cerebral malaria. Lancet (1988) 1.55
Synergism of multiple adhesion molecules in mediating cytoadherence of Plasmodium falciparum-infected erythrocytes to microvascular endothelial cells under flow. Blood (2000) 1.54
Identification of cryptic coinfection with Plasmodium falciparum in patients presenting with vivax malaria. Am J Trop Med Hyg (2001) 1.54
Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (2000) 1.52
Do patients with cerebral malaria have cerebral oedema? A computed tomography study. Lancet (1983) 1.50
A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and -negative erythrocytes. Blood (2001) 1.49
Quinine and quinidine: a comparison of EKG effects during the treatment of malaria. J Cardiovasc Pharmacol (1983) 1.49
Differential regulation of IgG subclasses and IgE antimalarial antibody responses in complicated and uncomplicated Plasmodium falciparum malaria. Parasite Immunol (2007) 1.48
Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am J Trop Med Hyg (2001) 1.47
Measurement of serum nitrite/nitrate concentrations using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl (1998) 1.47
The production of vesicular stomatitis virus by antigen- or mitogen-stimulated lymphocytes and continuous lymphoblastoid lines. J Exp Med (1973) 1.47
Efficacy of quinine-tetracycline for acute uncomplicated falciparum malaria in Thailand. Lancet (1992) 1.46
Assessment of disease activity in rheumatoid arthritis using magnetic resonance imaging: quantification of pannus volume in the hands. Br J Rheumatol (1998) 1.45
Human cerebral malaria in Thailand: a clinico-pathological correlation. Immunol Lett (1990) 1.44
Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol (1999) 1.44
A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (2000) 1.43
Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria. Am J Trop Med Hyg (1989) 1.43
Dynamic alteration in splenic function during acute falciparum malaria. N Engl J Med (1987) 1.40
Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol (1991) 1.39
Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria. Southeast Asian J Trop Med Public Health (1991) 1.37
Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans R Soc Trop Med Hyg (1998) 1.36
Quinine and severe falciparum malaria in late pregnancy. Lancet (1985) 1.34
Helminth infections are associated with protection from malaria-related acute renal failure and jaundice in Thailand. Am J Trop Med Hyg (2001) 1.34
Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother (2003) 1.34
Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg (2002) 1.33
High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg (1994) 1.33
Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg (1999) 1.31
Clinical correlates of in vitro Plasmodium falciparum cytoadherence. Infect Immun (1991) 1.30
Mapping soil-transmitted helminths in Southeast Asia and implications for parasite control. Southeast Asian J Trop Med Public Health (2003) 1.30
Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine (1994) 1.30
Studies on the interactions between viruses and lymphocytes. Cold Spring Harb Symp Quant Biol (1977) 1.30
Cardiovascular toxicity and distribution kinetics of intravenous chloroquine. Br J Clin Pharmacol (1986) 1.30
A study of the factors affecting the metabolic clearance of quinine in malaria. Eur J Clin Pharmacol (1997) 1.28
Safety of the insect repellent N,N-diethyl-M-toluamide (DEET) in pregnancy. Am J Trop Med Hyg (2001) 1.28
Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur J Clin Pharmacol (1997) 1.28
No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg (1999) 1.28
Quinine loading dose in cerebral malaria. Am J Trop Med Hyg (1983) 1.28
Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health (2003) 1.28
Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health (2001) 1.27
Interleukin-10 inhibits tumor necrosis factor production but not antigen-specific lymphoproliferation in acute Plasmodium falciparum malaria. J Infect Dis (1995) 1.26
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis (1999) 1.26
Can treatment of P. vivax lead to a unexpected appearance of falciparum malaria? Southeast Asian J Trop Med Public Health (2001) 1.25